Jul. 4 at 2:04 PM
$CLSD SANTEN...
We all know recently this company made a distribution deal with Arctic Vision to sell their version of Xipere in China after Chinese approval.
https://www.arcticvision.com/newsdetail/id/70.html
Did you know Santen (USA affiliate) back in 2013-2015 did work with CLSD
https://ir.clearsidebio.com/news-releases/news-release-details/santen-pharmaceutical-co-ltd-and-clearside-biomedical-inc-enter
Santen and Clearside extended relationship in 2015 against Glaucoma:
https://www.fiercepharma.com/drug-delivery/santen-clearside-biomedical-collaborate-on-glaucoma-lipocine-completes-trials-of-its
One of Santen's core areas of interest is wAMD
https://www.santen.com/en/business/rd/interest
GROK: Cash Reserves: Santen likely has a lot of cash reserves (estimated at
$200–400 million or more), based on its
$1.97 billion revenue, 36% net income growth , and ongoing share buyback program as of June 2025. This liquidity positions Santen to afford Clearside’s modest
$65.6 million market cap, especially given Clearside’s cash constraints
Clearside’s need for capital to fund PH3 trials for CLS-AX makes it an attractive acquisition target, which could provide the necessary funding to advance Clearside’s programs while integrating its technology.
